May the Nuclear Medicine Be with You! Neuroendocrine Tumours and the Return of Nuclear Medicine

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2024 Aug 19

PMID 39158585

Authors

Ozgul Ekmekcioglu

Simon Hughes

Wolfgang P Fendler

Fred Verzijlbergen

Grace Kong

Michael S Hofman

Affiliations

Soon will be listed here.

References

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B . Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2):125-135. PMC: 5895095. DOI: 10.1056/NEJMoa1607427. View

Kulke M, Anthony L, Bushnell D, de Herder W, Goldsmith S, Klimstra D . NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010; 39(6):735-52. PMC: 3100728. DOI: 10.1097/MPA.0b013e3181ebb168. View

Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J . Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021; 146:56-73. PMC: 8903070. DOI: 10.1016/j.ejca.2021.01.008. View

Delpassand E, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A . Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial. J Nucl Med. 2020; 61(6):890-896. DOI: 10.2967/jnumed.119.236091. View

Michalski K, Laubner K, Stoykow C, Omrane M, Maecke H, Seufert J . Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT. Clin Nucl Med. 2020; 45(7):519-524. DOI: 10.1097/RLU.0000000000003093. View

Rinke A, Muller H, Schade-Brittinger C, Klose K, Barth P, Wied M . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27(28):4656-63. DOI: 10.1200/JCO.2009.22.8510. View

Caplin M, Pavel M, Ruszniewski P . Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371(16):1556-7. DOI: 10.1056/NEJMc1409757. View

Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress T . Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology. 2016; 104(1):26-32. DOI: 10.1159/000443612. View

Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015; 387(10022):968-977. PMC: 6063317. DOI: 10.1016/S0140-6736(15)00817-X. View

10.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

11.

Baum R, Zhang J, Schuchardt C, Muller D, Macke H . First-in-Humans Study of the SSTR Antagonist Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med. 2021; 62(11):1571-1581. PMC: 8612334. DOI: 10.2967/jnumed.120.258889. View

12.

Delpassand E, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A . Targeted -Emitter Therapy with Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. J Nucl Med. 2022; 63(9):1326-1333. PMC: 9454455. DOI: 10.2967/jnumed.121.263230. View

13.

Kong G, Thompson M, Collins M, Herschtal A, Hofman M, Johnston V . Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). Eur J Nucl Med Mol Imaging. 2014; 41(10):1831-44. PMC: 4159597. DOI: 10.1007/s00259-014-2788-5. View

14.

Claringbold P, Turner J . Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy. Neuroendocrinology. 2015; 103(5):432-9. DOI: 10.1159/000434723. View

15.

Kennedy K, Turner J, MacDonald W, Claringbold P, Boardman G, Ransom D . Long-term survival and toxicity in patients with neuroendocrine tumors treated with Lu-octreotate peptide radionuclide therapy. Cancer. 2022; 128(11):2182-2192. DOI: 10.1002/cncr.34191. View

16.

Parghane R, Ostwal V, Ramaswamy A, Bhandare M, Chaudhari V, Talole S . Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging. 2020; 48(3):913-923. DOI: 10.1007/s00259-020-05004-5. View

17.

Nonnekens J, van Kranenburg M, Beerens C, Suker M, Doukas M, van Eijck C . Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. Theranostics. 2016; 6(11):1821-32. PMC: 4997239. DOI: 10.7150/thno.15311. View

18.

Cullinane C, Waldeck K, Kirby L, Rogers B, Eu P, Tothill R . Enhancing the anti-tumour activity of Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Sci Rep. 2020; 10(1):10196. PMC: 7311440. DOI: 10.1038/s41598-020-67199-9. View

19.

Veenstra M, Van Koetsveld P, Dogan F, Farrell W, Feelders R, Lamberts S . Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget. 2018; 9(19):14791-14802. PMC: 5871078. DOI: 10.18632/oncotarget.9462. View

20.

Taelman V, Radojewski P, Marincek N, Ben-Shlomo A, Grotzky A, Olariu C . Upregulation of Key Molecules for Targeted Imaging and Therapy. J Nucl Med. 2016; 57(11):1805-1810. DOI: 10.2967/jnumed.115.165092. View